Scarica l'app Stockscreener
9.58
0.10%
-0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$9.59
Aprire:
$9.71
Volume 24 ore:
225.23K
Relative Volume:
0.16
Capitalizzazione di mercato:
$81.55M
Reddito:
$120.77M
Utile/perdita netta:
$32.69M
Rapporto P/E:
3.2869
EPS:
2.9146
Flusso di cassa netto:
$-50.94M
1 W Prestazione:
+14.87%
1M Prestazione:
+82.82%
6M Prestazione:
-30.38%
1 anno Prestazione:
+25.89%
Intervallo 1D:
$8.65
$9.8051
Intervallo di 1 settimana:
$7.90
$10.80
Portata 52W:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.58 | 81.63M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action ... - Caledonian Record
The Gross Law Firm Reminds Atara Biotherapeutics, Inc. - GlobeNewswire
Redmile funds disclose 9.9% Atara Biotherapeutics (ATRA) stake via warrants cap - Stock Titan
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ATARA DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, - GlobeNewswire
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
Manufacturing and Supply-Chain Risks Threaten Atara Biotherapeutics’ Cell Therapy Pipeline - TipRanks
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - lincolnjournal.com
8-K: Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progressmoomoo - Moomoo
Atara Biotherapeutics | 424B5: Prospectus - Moomoo
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - The National Law Review
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Adage and principals report 8.56% stake in Atara (NASDAQ: ATRA) - Stock Titan
Atara Biotherapeutics: Runway Into Mid-2027 >ATRA - Moomoo
Atara Biotherapeutics (ATRA) Eps Diluted (TTM) - Zacks Investment Research
Atara (ATRA) Provides Update on BLA Resubmission and Financial S - GuruFocus
Atara Biotherapeutics 1Q Loss/Shr 29c >ATRA - Moomoo
Atara BiotherapeuticsMay Offer Up To $79.27 Million In Common Stock As Of May 12, 2026SEC Filing - TradingView
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Dead - GuruFocus
Atara Biotherapeutics: Q1 Earnings Snapshot - WKYC
FinancialContentPomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - FinancialContent
Atara Biotherapeutics (NASDAQ: ATRA) adds $79.27M to ATM sales agreement - Stock Titan
[10-Q] Atara Biotherapeutics, Inc. Quarterly Earnings Report - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) Q1 2026 loss and cash runway update - Stock Titan
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Atara Biotherapeutics | SCHEDULE 13D/A: Others - Moomoo
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Atara Biotherapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Barchart.com
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Atara Biotherapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
MSN Money - MSN
Atara Biotherapeutics | 3: Initial statement of beneficial ownership of securities- EcoR1 Capital, LLC - Moomoo
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara biotherapeutics director James Huang sells $3.16m in stock By Investing.com - Investing.com Australia
Atara biotherapeutics director James Huang sells $3.16m in stock - Investing.com
Panacea funds cut Atara (ATRA) stake but remain 16.1% holder - Stock Titan
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Panacea Innovation Ltdmoomoo - Moomoo
Panacea funds linked to Atara (NASDAQ: ATRA) director sell 313,446 shares - Stock Titan
EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock By Investing.com - Investing.com South Africa
EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock - Investing.com
EcoR1 Capital (NASDAQ: ATRA) adds 507K Atara shares in open-market buy - Stock Titan
EcoR1 Capital (NASDAQ: ATRA) reports initial 1.04M-share Atara stake - Stock Titan
Atara Biotherapeutics, Inc. Sued for Securities Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
Atara Biotherapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRA Stockholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atara Biotherapeutics Inc Azioni (ATRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 07 '26 |
Buy |
9.35 |
507,407 |
4,744,255 |
1,552,000 |
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):